心血管疾病早期生物标志物筛选与临床应用研究进展
Research Progress on the Screening and Clinical Application of Early Biomarkers for Cardiovascular Diseases
摘要: 为了提升对心血管疾病早期诊断的临床效果，本文系统综述了心血管疾病早期生物标志物的研究进展，重点介绍了蛋白质组学、代谢组学和基因组学等多组学技术在新型标志物筛选中的应用。文章分析了传统标志物(如LDL-C、hs-CRP)与新兴标志物(如Lp(a)、非编码RNA)在早期诊断、风险分层和个体化治疗中的价值，并探讨了多标志物联合策略的临床优势。同时，针对生物标志物转化应用中的标准化、验证及解读挑战提出展望，强调通过多组学整合与人工智能技术推动心血管疾病防治向精准预防模式转变。
Abstract: To enhance the clinical efficacy of early diagnosis of cardiovascular diseases, this article systematically reviews the research progress of early biomarkers for cardiovascular diseases, with a focus on the application of multi-omics technologies such as proteomics, metabolomics, and genomics in the screening of novel biomarkers. The article analyzes the value of traditional biomarkers (such as LDL-C, hs-CRP) and emerging biomarkers (such as Lp(a), non-coding RNA) in early diagnosis, risk stratification, and individualized treatment, and discusses the clinical advantages of multi-biomarker combination strategies. At the same time, it offers prospects for the challenges of standardization, validation, and interpretation in the translational application of biomarkers, emphasizing the promotion of the prevention and treatment of cardiovascular diseases towards a precision prevention model through the integration of multi-omics and artificial intelligence technologies.
文章引用：王子阳. 心血管疾病早期生物标志物筛选与临床应用研究进展[J]. 亚洲心脑血管病例研究, 2025, 13(4): 51-56. https://doi.org/10.12677/acrvm.2025.134006

参考文献

[1] 刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》概要(心血管疾病流行及介入诊疗状况) [J]. 中国介入心脏病学杂志, 2024, 32(10): 541-550.
[2] 陈子健, 沈逸凡, 华召筛. 心脏标志物在心血管疾病诊断中的应用进展[J]. 临床医学研究与实践, 2024, 9(21): 190-194.
[3] 陈映泉, 钟勇. 心血管老化的机制、标志物和治疗[J]. 实用老年医学, 2024, 38(3): 299-303.
[4] 宋雷, 惠汝太. 心血管疾病与精准医学[M]. 北京: 人民卫生出版社, 2020: 3-19.
[5] 阿尔达克·哈盘. 心电图与高灵敏度肌钙蛋白Ⅰ在急性心肌梗死中的诊断价值[J]. 贵州医药, 2025, 49(8): 1290-1291.
[6] Zhou, X., Sun, X.H., Zhao, H.W., et al. (2024) Biomarker Identification and Risk Assessment of Cardiovascular Disease Based on Untargeted Metabolomics and Machine Learning. Scientific Reports, 14, Article No. 25755. [Google Scholar] [CrossRef] [PubMed]
[7] 胡昊, 李茜楠, 王腾玉, 等. 动脉粥样硬化不稳定斑块的蛋白质组学研究的进展[J]. 心血管康复医学杂志, 2022, 31(3): 354-357.
[8] 吕晶, 吕果. 体外与非体外循环冠状动脉旁路移植术后血清miR-1、miR-133a、miR-208a水平变化及分析[J]. 中国动脉硬化杂志, 2021, 29(9): 794-798, 818.
[9] 温小云, 方先松, 沈志明. Lp(a)的颗粒浓度在评估心血管风险中的应用价值[J]. 中国医学创新, 2018, 15(32): 19-23.
[10] 孙涛, 张艳丽, 侯梅凤, 等. 血清脂蛋白(a) [Lp(a)]、血清超敏C反应蛋白(hs-CRP)与冠状动脉慢血流之间的相关性[J]. 系统医学, 2021, 6(22): 32-36.
[11] 丁宇敏, 王海玉, 李德红. 神经元特异性烯醇化酶在脑部疾病中的研究进展[J]. 检验医学与临床, 2024, 21(17): 2612-2616.
[12] Mohamed, A.A.O., Omer, S.S.B., Mukhtar, M., et al. (2025) The Role of Epicardial Fat Thickness and B-Type Natriuretic Peptide (BNP)/N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) in Heart Failure Risk Stratification: A Systematic Review. Cureus, 17, e84184.
[13] Berge, K., Lyngbakken, M.N., Myhre, P.L., Brynildsen, J., Røysland, R., Strand, H., et al. (2021) High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide in Acute Heart Failure: Data from the ACE 2 Study. Clinical Biochemistry, 88, 30-36. [Google Scholar] [CrossRef] [PubMed]
[14] 赵美丽, 肖立运, 刘林, 等. NT-proBNP、hs-CRP、LAD与慢性心力衰竭合并心房颤动的相关性[J]. 临床荟萃, 2021, 36(5): 412-415.

为你推荐